Influenza A M2 Inhibitor Binding Understood through Mechanisms of Excess Proton Stabilization and Channel Dynamics
Abstract
Prevalent resistance to inhibitors that target the influenza A M2 proton channel has necessitated a continued drug design effort, supported by a sustained study of the mechanism of channel function and inhibition. Recent high-resolution X-ray crystal structures present the first opportunity to see how the adamantyl-amine class of inhibitors bind to M2 and disrupt and interact with the channels water network, providing insight into the critical properties that enable their effective inhibition in wildtype M2. In this work, we test the hypothesis that these drugs act primarily as mechanism-based inhibitors by comparing hydrated excess proton stabilization during proton transport in M2 with the interactions revealed in the crystal structures, using the Multiscale Reactive Molecular Dynamics (MS-RMD) methodology. MS-RMD, unlike classical molecular dynamics, models the hydrated proton (hydronium-like cation) as a dynamic excess charge defect and allows bonds to break and form, capturing the intricate interactions between the hydrated excess proton, protein atoms, and water. Through this, we show that the ammonium group of the inhibitors is effectively positioned to take advantage of the channels natural ability to stabilize an excess protonic charge and is thus acting as a hydronium-mimic. Additionally, we show that the channel is especially stable in the drug binding region, highlighting the importance of this property for binding the adamantane group. Finally, we characterize an additional hinge point near Val27, which dynamically responds to charge and inhibitor binding. Altogether, this work further illuminates a dynamic understanding of the mechanism of drug inhibition in M2, grounded in the fundamental properties that enable the channel to transport and stabilize excess protons, with critical implications for future drug design efforts. TOC Graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=172 SRC="FIGDIR/small/162248v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@aee3a3org.highwire.dtl.DTLVardef@1e3058forg.highwire.dtl.DTLVardef@1820aecorg.highwire.dtl.DTLVardef@9b32ae_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Activation of the influenza B M2 proton channel (BM2)
Zhi Yue, Jiangbo Wu, … Gregory A. Voth·BiochemistryPeer-reviewed·Nov 3, 2024
- Mechanism and kinetics of copper complexes binding to the influenza A M2 channel
D. D. Busath, K. L. McGuire, … J. T. Hill·bioRxiv·Aug 24, 2020
- Real-time tracking of drug binding to Influenza A M2 reveals a high energy barrier
K. Tekwani Movellan, M. Wegstroth, … L. B. Andreas·bioRxiv·Apr 7, 2023
- Multiscale Simulation of an Influenza A M2 Channel Mutant Reveals Key Features of Its Markedly Different Proton Transport Behavior
L. C. Watkins, W. F. DeGrado, G. A. Voth·bioRxiv·Sep 7, 2021
- Exploring polycyclic scaffolds as adamantane replacements in M2 channel inhibitors of Influenza A virus
Andreea L. Turcu, Rosana Leiva, … Santiago Vázquez·bioRxiv·Jul 26, 2025
- Influenza A M2 Channel Oligomerization is Sensitive to its Chemical Environment
J. A. Townsend, H. M. Sanders, … M. T. Marty·bioRxiv·May 7, 2021